mometasone inhaled/formoterol (Rx)

Brand and Other Names:Dulera
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

mometasone/formoterol

aerosol

  • (50mcg/5mcg)/actuation
  • (100mcg/5mcg)/actuation
  • (200mcg/5mcg)/actuation

Asthma

Indicated for asthma in patients who are not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA)

Initial: 200 mcg/10 mcg (2 actuations of 100 mcg/5 mcg) inhaled PO q12hr; may increase to higher dose after 2 wk if inadequate response; maximum benefit may not be achieved for 1 week or longer after beginning treatment

Severe asthma (initial) or inadequate response to lower dose (after 2 wk): 400 mcg/10 mcg (2 actuations of 200 mcg/5 mcg) inhaled PO q12hr

Not to exceed more than 2 inhalations twice daily of prescribed strength

Maximum daily dose: 800 mcg/20 mcg daily (ie, 2 actuations of 200 mcg/5 mcg q12hr)If therapy fails to provide adequate control of asthma, re-evaluate therapeutic regimen; consider replacing with higher strength, adding additional inhaled corticosteroid, or initiating oral corticosteroids

If symptoms arise between doses, an inhaled short-acting beta2-agonist should be taken for immediate relief

Dosing Considerations

Limitation of use

  • Not indicated for the relief of acute bronchospasm

Dosage Forms & Strengths

mometasone/formoterol

aerosol

  • (50mcg/5mcg)/actuation
  • (100mcg/5mcg)/actuation
  • (200mcg/5mcg)/actuation

Asthma

Indicated for asthma in patients who are not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA)

<5 years: Safety and efficacy not established

5 to <12 years

  • 100 mcg/10 mcg (2 actuations of 50 mcg/5 mcg) inhaled PO q12hr; maximum daily dosage is 200 mcg/20 mcg

≥12 years

  • Initial: 200 mcg/10 mcg (2 actuations of 100 mcg/5 mcg) inhaled PO q12hr; may increase to higher dose after 2 wk if inadequate response; maximum benefit may not be achieved for 1 week or longer after beginning treatment
  • Severe asthma (initial) or inadequate response to lower dose (after 2 wk): 400 mcg/10 mcg (2 actuations of 200 mcg/5 mcg) inhaled PO q12hr
  • Not to exceed more than 2 inhalations twice daily of prescribed strength
  • Maximum daily dose: 800 mcg/20 mcg daily (ie, 2 actuations of 200 mcg/5 mcg q12hr)
  • If therapy fails to provide adequate control of asthma, re-evaluate therapeutic regimen; consider replacing with higher strength, adding additional inhaled corticosteroid, or initiating oral corticosteroids
  • If symptoms arise between doses, an inhaled short-acting beta2-agonist should be taken for immediate relief

Dosing Considerations

Limitations of use

  • Not indicated for the relief of acute bronchospasm
Next:

Interactions

Interaction Checker

and mometasone inhaled/formoterol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (40)

              • aldesleukin

                mometasone inhaled decreases effects of aldesleukin by Other (see comment). Avoid or Use Alternate Drug. Comment: Corticosteroids may interfere with antitumor effects of aldesleukin.

              • amitriptyline

                amitriptyline and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                amitriptyline, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • amoxapine

                amoxapine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                amoxapine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • arformoterol

                arformoterol and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • artemether/lumefantrine

                formoterol and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

              • chlorpromazine

                chlorpromazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • clarithromycin

                clarithromycin and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • clomipramine

                clomipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                clomipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • desipramine

                desipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                desipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • desmopressin

                mometasone inhaled increases toxicity of desmopressin by Other (see comment). Avoid or Use Alternate Drug. Comment: Corticosteroids may enhance the hyponatremic effect of intranasal desmopressin.

              • disopyramide

                disopyramide and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • dofetilide

                dofetilide and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • doxepin

                doxepin and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                doxepin, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • dronedarone

                dronedarone and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • droperidol

                droperidol and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • entrectinib

                formoterol and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.

              • epinephrine

                epinephrine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • epinephrine racemic

                epinephrine racemic and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • erythromycin base

                erythromycin base and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • erythromycin ethylsuccinate

                erythromycin ethylsuccinate and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • erythromycin lactobionate

                erythromycin lactobionate and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • erythromycin stearate

                erythromycin stearate and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • fexinidazole

                fexinidazole and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

              • fluconazole

                fluconazole and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • fluphenazine

                fluphenazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • glasdegib

                formoterol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.

              • haloperidol

                formoterol and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.

              • hydroxychloroquine sulfate

                hydroxychloroquine sulfate and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • ibutilide

                formoterol and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.

              • imipramine

                imipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                imipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • indapamide

                formoterol and indapamide both increase QTc interval. Avoid or Use Alternate Drug.

              • inotuzumab

                inotuzumab and formoterol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

              • isocarboxazid

                isocarboxazid increases effects of formoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • ivosidenib

                ivosidenib and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

              • ketoconazole

                formoterol and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

              • lefamulin

                lefamulin and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

              • linezolid

                linezolid increases effects of formoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

              • lofepramine

                lofepramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

                lofepramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

              • loxapine inhaled

                mometasone inhaled increases toxicity of loxapine inhaled by Other (see comment). Avoid or Use Alternate Drug. Comment: Agents used to treat airway disease may enhance the toxic effect of inhaled loxapine.

              • lumefantrine

                formoterol and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

              Monitor Closely (300)

              • acebutolol

                acebutolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                acebutolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • aceclofenac

                aceclofenac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • acemetacin

                acemetacin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • albuterol

                albuterol and formoterol both decrease serum potassium. Use Caution/Monitor.

                albuterol and formoterol both decrease sedation. Use Caution/Monitor.

                albuterol and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • alfentanil

                alfentanil increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • alfuzosin

                formoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.

                alfuzosin and formoterol both increase QTc interval. Use Caution/Monitor.

              • alprazolam

                alprazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • amiloride

                amiloride increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • amiodarone

                amiodarone and formoterol both increase QTc interval. Use Caution/Monitor.

              • amitriptyline

                amitriptyline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • amobarbital

                amobarbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • amoxapine

                amoxapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • amphotericin B deoxycholate

                mometasone inhaled increases toxicity of amphotericin B deoxycholate by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may enhance the hypokalemic effect of amphtericin B. .

              • apomorphine

                apomorphine and formoterol both increase QTc interval. Use Caution/Monitor.

              • arformoterol

                arformoterol and formoterol both decrease serum potassium. Use Caution/Monitor.

                arformoterol and formoterol both decrease sedation. Use Caution/Monitor.

                arformoterol and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • aripiprazole

                aripiprazole increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                aripiprazole and formoterol both increase QTc interval. Use Caution/Monitor.

              • armodafinil

                formoterol and armodafinil both decrease sedation. Use Caution/Monitor.

              • arsenic trioxide

                arsenic trioxide and formoterol both increase QTc interval. Use Caution/Monitor.

              • artemether

                artemether and formoterol both increase QTc interval. Use Caution/Monitor.

              • aspirin

                aspirin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • aspirin rectal

                aspirin rectal increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • aspirin/citric acid/sodium bicarbonate

                aspirin/citric acid/sodium bicarbonate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • atazanavir

                atazanavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • atenolol

                atenolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                atenolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • atomoxetine

                formoterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .

                atomoxetine and formoterol both increase QTc interval. Use Caution/Monitor.

              • azelastine

                azelastine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • azithromycin

                azithromycin and formoterol both increase QTc interval. Use Caution/Monitor.

              • bedaquiline

                formoterol and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

              • belladonna and opium

                belladonna and opium increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • bendroflumethiazide

                formoterol and bendroflumethiazide both decrease serum potassium. Use Caution/Monitor.

              • benperidol

                benperidol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • benzphetamine

                formoterol and benzphetamine both decrease sedation. Use Caution/Monitor.

                formoterol and benzphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • betaxolol

                betaxolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                betaxolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • bisoprolol

                bisoprolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                bisoprolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • brompheniramine

                brompheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • bumetanide

                formoterol and bumetanide both decrease serum potassium. Use Caution/Monitor.

                mometasone inhaled increases toxicity of bumetanide by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

              • buprenorphine buccal

                buprenorphine buccal increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ceritinib

                mometasone inhaled increases toxicity of ceritinib by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypoglycemic effects of ceritinib.

              • butabarbital

                butabarbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • butalbital

                butalbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • butorphanol

                butorphanol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • caffeine

                formoterol and caffeine both decrease sedation. Use Caution/Monitor.

              • carbenoxolone

                formoterol and carbenoxolone both decrease serum potassium. Use Caution/Monitor.

              • carbinoxamine

                carbinoxamine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • carvedilol

                carvedilol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                carvedilol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • celecoxib

                celecoxib increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • celiprolol

                celiprolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                celiprolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • ceritinib

                ceritinib and formoterol both increase QTc interval. Use Caution/Monitor.

              • chloral hydrate

                chloral hydrate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • chlordiazepoxide

                chlordiazepoxide increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • chlorothiazide

                mometasone inhaled increases toxicity of chlorothiazide by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

                formoterol and chlorothiazide both decrease serum potassium. Use Caution/Monitor.

              • chlorpheniramine

                chlorpheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • chlorthalidone

                mometasone inhaled increases toxicity of chlorthalidone by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

              • chlorpromazine

                chlorpromazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • chlorthalidone

                formoterol and chlorthalidone both decrease serum potassium. Use Caution/Monitor.

              • choline magnesium trisalicylate

                choline magnesium trisalicylate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • cinnarizine

                cinnarizine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ciprofloxacin

                mometasone inhaled and ciprofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.

              • clarithromycin

                clarithromycin will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases riak for systemic corticosteroid side effects

              • clemastine

                clemastine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • clomipramine

                clomipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • clonazepam

                clonazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • clorazepate

                clorazepate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • clozapine

                clozapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • cobicistat

                cobicistat will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases risk for systemic corticosteroid side effects

              • codeine

                codeine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • corticorelin

                mometasone inhaled decreases effects of corticorelin by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may blunt plasma ACTH response to corticorelin.

              • cyclizine

                cyclizine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • cyclopenthiazide

                formoterol and cyclopenthiazide both decrease serum potassium. Use Caution/Monitor.

              • cyproheptadine

                cyproheptadine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • darunavir

                darunavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • dasatinib

                dasatinib and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.

              • deferasirox

                mometasone inhaled increases toxicity of deferasirox by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids increase risk of gastrointestinal ulceration/irritation.

              • deflazacort

                formoterol and deflazacort both decrease serum potassium. Use Caution/Monitor.

              • degarelix

                degarelix and formoterol both increase QTc interval. Use Caution/Monitor.

              • desipramine

                desipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexchlorpheniramine

                dexchlorpheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexfenfluramine

                formoterol and dexfenfluramine both decrease sedation. Use Caution/Monitor.

                formoterol and dexfenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • dexmedetomidine

                dexmedetomidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmethylphenidate

                formoterol and dexmethylphenidate both decrease sedation. Use Caution/Monitor.

                formoterol and dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • dextroamphetamine

                formoterol and dextroamphetamine both decrease sedation. Use Caution/Monitor.

                formoterol and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • dextromoramide

                dextromoramide increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • diamorphine

                diamorphine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dichlorphenamide

                dichlorphenamide and formoterol both decrease serum potassium. Use Caution/Monitor.

                dichlorphenamide, formoterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

              • diclofenac

                diclofenac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • diethylpropion

                formoterol and diethylpropion both decrease sedation. Use Caution/Monitor.

                formoterol and diethylpropion both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • difenoxin hcl

                difenoxin hcl increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • diflunisal

                diflunisal increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • digoxin

                digoxin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dimenhydrinate

                dimenhydrinate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • diphenhydramine

                diphenhydramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • diphenoxylate hcl

                diphenoxylate hcl increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dipipanone

                dipipanone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dobutamine

                dobutamine and formoterol both decrease serum potassium. Use Caution/Monitor.

                dobutamine and formoterol both decrease sedation. Use Caution/Monitor.

                dobutamine and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • dolasetron

                dolasetron and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.

              • donepezil

                donepezil and formoterol both increase QTc interval. Use Caution/Monitor.

              • dopamine

                formoterol and dopamine both decrease sedation. Use Caution/Monitor.

                formoterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • dopexamine

                dopexamine and formoterol both decrease serum potassium. Use Caution/Monitor.

                dopexamine and formoterol both decrease sedation. Use Caution/Monitor.

                dopexamine and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                dopexamine, formoterol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

              • doxepin

                doxepin increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • droperidol

                droperidol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • drospirenone

                drospirenone increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • elvitegravir/cobicistat/emtricitabine/tenofovir DF

                elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases riak for systemic corticosteroid side effects

              • ephedrine

                ephedrine and formoterol both decrease serum potassium. Use Caution/Monitor.

                ephedrine and formoterol both decrease sedation. Use Caution/Monitor.

                ephedrine and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • epinephrine

                epinephrine and formoterol both decrease serum potassium. Use Caution/Monitor.

                epinephrine and formoterol both decrease sedation. Use Caution/Monitor.

                epinephrine and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • epinephrine racemic

                formoterol and epinephrine racemic both decrease serum potassium. Use Caution/Monitor.

                formoterol and epinephrine racemic both decrease sedation. Use Caution/Monitor.

                formoterol and epinephrine racemic both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • escitalopram

                escitalopram increases toxicity of formoterol by QTc interval. Use Caution/Monitor.

              • esmolol

                esmolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                esmolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • estazolam

                estazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ethacrynic acid

                formoterol and ethacrynic acid both decrease serum potassium. Use Caution/Monitor.

                mometasone inhaled increases toxicity of ethacrynic acid by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

              • ethanol

                ethanol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fosamprenavir

                fosamprenavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • etodolac

                etodolac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fenfluramine

                formoterol and fenfluramine both decrease sedation. Use Caution/Monitor.

                formoterol and fenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • fenoprofen

                fenoprofen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • flecainide

                flecainide and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.

              • fluoxetine

                fluoxetine and formoterol both increase QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system

              • fluphenazine

                fluphenazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • flurazepam

                flurazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • flurbiprofen

                flurbiprofen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fluvoxamine

                fluvoxamine and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.

              • foscarnet

                formoterol and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.

              • fostemsavir

                formoterol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

              • furosemide

                formoterol and furosemide both decrease serum potassium. Use Caution/Monitor.

                mometasone inhaled increases toxicity of furosemide by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

              • gemifloxacin

                mometasone inhaled and gemifloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.

              • gentamicin

                formoterol and gentamicin both decrease serum potassium. Use Caution/Monitor.

              • goserelin

                goserelin increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • haloperidol

                haloperidol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • histrelin

                histrelin increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • hyaluronidase

                mometasone inhaled decreases effects of hyaluronidase by Other (see comment). Modify Therapy/Monitor Closely. Comment: Corticosteroids may decrease therapeutic effects of hyaluronidase.

              • hydrochlorothiazide

                mometasone inhaled increases toxicity of hydrochlorothiazide by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

                formoterol and hydrochlorothiazide both decrease serum potassium. Use Caution/Monitor.

              • hydromorphone

                hydromorphone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • indinavir

                indinavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • hydroxyzine

                hydroxyzine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ibuprofen

                ibuprofen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ibuprofen IV

                ibuprofen IV increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • iloperidone

                formoterol and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.

                iloperidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • imipramine

                imipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • indapamide

                formoterol and indapamide both decrease serum potassium. Use Caution/Monitor.

              • indomethacin

                indomethacin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • isoproterenol

                formoterol and isoproterenol both decrease serum potassium. Use Caution/Monitor.

                formoterol and isoproterenol both decrease sedation. Use Caution/Monitor.

                formoterol and isoproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • itraconazole

                itraconazole will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases risk for systemic corticosteroid side effects

              • ketoconazole

                ketoconazole will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases riak for systemic corticosteroid side effects

              • ketoprofen

                ketoprofen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ketorolac

                ketorolac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ketorolac intranasal

                ketorolac intranasal increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • ketotifen, ophthalmic

                ketotifen, ophthalmic increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • labetalol

                labetalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                labetalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • lapatinib

                formoterol and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.

              • lenvatinib

                formoterol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.

              • letermovir

                letermovir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • leuprolide

                leuprolide increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • levalbuterol

                formoterol and levalbuterol both decrease serum potassium. Use Caution/Monitor.

                formoterol and levalbuterol both decrease sedation. Use Caution/Monitor.

                formoterol and levalbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • levofloxacin

                mometasone inhaled and levofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.

                formoterol and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

              • levorphanol

                levorphanol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lopinavir

                lopinavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • lisdexamfetamine

                formoterol and lisdexamfetamine both decrease sedation. Use Caution/Monitor.

                formoterol and lisdexamfetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • lofepramine

                lofepramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lofexidine

                lofexidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • loprazolam

                loprazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lorazepam

                lorazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lormetazepam

                lormetazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lornoxicam

                lornoxicam increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • loxapine

                loxapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • loxapine inhaled

                loxapine inhaled increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • maprotiline

                maprotiline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • marijuana

                marijuana increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • meclofenamate

                meclofenamate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • mefenamic acid

                mefenamic acid increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • melatonin

                melatonin increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • meloxicam

                meloxicam increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • meperidine

                meperidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • meprobamate

                meprobamate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • metaproterenol

                formoterol and metaproterenol both decrease serum potassium. Use Caution/Monitor.

                formoterol and metaproterenol both decrease sedation. Use Caution/Monitor.

                formoterol and metaproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • methadone

                formoterol and methadone both increase QTc interval. Modify Therapy/Monitor Closely.

                methadone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • methamphetamine

                formoterol and methamphetamine both decrease sedation. Use Caution/Monitor.

                formoterol and methamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • methyclothiazide

                formoterol and methyclothiazide both decrease serum potassium. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                formoterol and methylenedioxymethamphetamine both decrease sedation. Use Caution/Monitor.

                formoterol and methylenedioxymethamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • methylphenidate

                formoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • metolazone

                formoterol and metolazone both decrease serum potassium. Use Caution/Monitor.

              • metoprolol

                metoprolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                metoprolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • midazolam

                midazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midodrine

                formoterol and midodrine both decrease sedation. Use Caution/Monitor.

                formoterol and midodrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • mifepristone

                mifepristone, formoterol. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

              • mirtazapine

                mirtazapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • modafinil

                formoterol and modafinil both decrease sedation. Use Caution/Monitor.

              • morphine

                morphine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • motherwort

                motherwort increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • moxifloxacin

                mometasone inhaled and moxifloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.

              • moxonidine

                moxonidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nabilone

                nabilone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nabumetone

                nabumetone increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nadolol

                nadolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                nadolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • nalbuphine

                nalbuphine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • naproxen

                naproxen increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nebivolol

                nebivolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                nebivolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • nefazodone

                nefazodone will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases riak for systemic corticosteroid side effects

              • nelfinavir

                nelfinavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • norepinephrine

                formoterol and norepinephrine both decrease serum potassium. Use Caution/Monitor.

                formoterol and norepinephrine both decrease sedation. Use Caution/Monitor.

                formoterol and norepinephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • nortriptyline

                nortriptyline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ofloxacin

                formoterol and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

                mometasone inhaled and ofloxacin both increase Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.

              • olanzapine

                olanzapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ribociclib

                ribociclib will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • olodaterol inhaled

                formoterol and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effects

              • opium tincture

                opium tincture increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • osilodrostat

                osilodrostat and formoterol both increase QTc interval. Use Caution/Monitor.

              • osimertinib

                osimertinib and formoterol both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

              • oxaliplatin

                oxaliplatin will increase the level or effect of formoterol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.

              • oxaprozin

                oxaprozin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • oxazepam

                oxazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • oxycodone

                oxycodone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • oxymorphone

                oxymorphone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ozanimod

                ozanimod and formoterol both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

              • paliperidone

                formoterol and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.

                paliperidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • papaveretum

                papaveretum increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • parecoxib

                parecoxib increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • paroxetine

                formoterol and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.

              • pasireotide

                formoterol and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

              • pazopanib

                formoterol and pazopanib both increase QTc interval. Use Caution/Monitor.

              • penbutolol

                penbutolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                penbutolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • pentazocine

                pentazocine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pentobarbital

                pentobarbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • perphenazine

                perphenazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phendimetrazine

                formoterol and phendimetrazine both decrease sedation. Use Caution/Monitor.

                formoterol and phendimetrazine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • phenobarbital

                phenobarbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenoxybenzamine

                phenoxybenzamine, formoterol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Hypotension, tachycardia.

              • phentermine

                formoterol and phentermine both decrease sedation. Use Caution/Monitor.

                formoterol and phentermine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • phenylephrine

                formoterol and phenylephrine both decrease sedation. Use Caution/Monitor.

                formoterol and phenylephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • phenylephrine PO

                formoterol and phenylephrine PO both decrease sedation. Use Caution/Monitor.

                formoterol and phenylephrine PO both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • pholcodine

                pholcodine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pimozide

                pimozide increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pindolol

                pindolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                pindolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • pirbuterol

                formoterol and pirbuterol both decrease serum potassium. Use Caution/Monitor.

                formoterol and pirbuterol both decrease sedation. Use Caution/Monitor.

                formoterol and pirbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • piroxicam

                piroxicam increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • posaconazole

                formoterol and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.

              • potassium acid phosphate

                potassium acid phosphate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • potassium chloride

                potassium chloride increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • potassium citrate

                potassium citrate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • primidone

                primidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • procarbazine

                procarbazine increases effects of formoterol by pharmacodynamic synergism. Use Caution/Monitor.

              • prochlorperazine

                prochlorperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • promethazine

                promethazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • propranolol

                propranolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                propranolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • propylhexedrine

                formoterol and propylhexedrine both decrease sedation. Use Caution/Monitor.

                formoterol and propylhexedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • protriptyline

                protriptyline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pseudoephedrine

                formoterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • quazepam

                quazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • quetiapine

                quetiapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • quinine

                formoterol and quinine both increase QTc interval. Use Caution/Monitor.

              • ranolazine

                formoterol and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.

              • ribociclib

                ribociclib increases toxicity of formoterol by QTc interval. Use Caution/Monitor.

              • risperidone

                formoterol and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.

                risperidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ritonavir

                ritonavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression.

              • sacubitril/valsartan

                sacubitril/valsartan increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • salicylates (non-asa)

                salicylates (non-asa) increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • salmeterol

                formoterol and salmeterol both decrease serum potassium. Use Caution/Monitor.

                formoterol and salmeterol both decrease sedation. Use Caution/Monitor.

                formoterol and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • salsalate

                salsalate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • saquinavir

                saquinavir will increase the level or effect of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increases riak for systemic corticosteroid side effects

              • scullcap

                scullcap increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • secobarbital

                secobarbital increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • selpercatinib

                selpercatinib increases toxicity of formoterol by QTc interval. Use Caution/Monitor.

              • shepherd's purse

                shepherd's purse increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol

                formoterol and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.

              • solriamfetol

                formoterol and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • sorafenib

                sorafenib and formoterol both increase QTc interval. Use Caution/Monitor.

              • sotalol

                sotalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                sotalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • spironolactone

                spironolactone increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • succinylcholine

                succinylcholine increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • sufentanil

                sufentanil increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • sulfamethoxazole

                sulfamethoxazole and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.

              • sulfasalazine

                sulfasalazine increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • sulindac

                sulindac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • tapentadol

                tapentadol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • telavancin

                formoterol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

              • temazepam

                temazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • terbutaline

                formoterol and terbutaline both decrease serum potassium. Use Caution/Monitor.

                formoterol and terbutaline both decrease sedation. Use Caution/Monitor.

                formoterol and terbutaline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • thioridazine

                thioridazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • thiothixene

                thiothixene increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • timolol

                timolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                timolol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

              • tolfenamic acid

                tolfenamic acid increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • tolmetin

                tolmetin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • tolvaptan

                tolvaptan increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • topiramate

                topiramate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • torsemide

                mometasone inhaled increases toxicity of torsemide by Other (see comment). Use Caution/Monitor. Comment: Corticosteroids may increase hypokalemic effect of loop diuretics.

                formoterol and torsemide both decrease serum potassium. Use Caution/Monitor.

              • tramadol

                tramadol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • trazodone

                trazodone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • triamterene

                triamterene increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • triazolam

                triazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • triclofos

                triclofos increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • trifluoperazine

                trifluoperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • trimethoprim

                formoterol and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.

              • trimipramine

                trimipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • triprolidine

                triprolidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • triptorelin

                triptorelin increases levels of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • tropisetron

                formoterol and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.

              • venlafaxine

                formoterol and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.

              • voriconazole

                formoterol and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.

              • xylometazoline

                formoterol and xylometazoline both decrease sedation. Use Caution/Monitor.

                formoterol and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • yohimbine

                formoterol and yohimbine both decrease sedation. Use Caution/Monitor.

                formoterol and yohimbine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • ziconotide

                ziconotide increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziprasidone

                ziprasidone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              Minor (17)

              • bendroflumethiazide

                formoterol, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • bumetanide

                formoterol, bumetanide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • chloroquine

                chloroquine increases toxicity of formoterol by QTc interval. Minor/Significance Unknown.

              • chlorothiazide

                formoterol, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • chlorthalidone

                formoterol, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • cyclopenthiazide

                formoterol, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • ethacrynic acid

                formoterol, ethacrynic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • eucalyptus

                eucalyptus increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.

              • furosemide

                formoterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • green tea

                green tea increases effects of formoterol by pharmacodynamic synergism. Minor/Significance Unknown. Due to caffeine content. Combination may increase CNS stimulatory effects due to caffeine in green tea.

              • hydrochlorothiazide

                formoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • indapamide

                formoterol, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • methyclothiazide

                formoterol, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • metolazone

                formoterol, metolazone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              • noni juice

                noni juice increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Minor/Significance Unknown.

              • sage

                sage increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.

              • torsemide

                formoterol, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.

              Previous
              Next:

              Adverse Effects

              1-10%

              Nasopharyngitis (4.7%)

              Headache (2-4.5%)

              Sinusitis (2-3.3%)

              <1%

              Oral candidiasis

              Postmarketing Reports

              Cardiac: Angina pectoris, cardiac arrhythmias (eg, atrial fibrillation, ventricular extrasystoles, tachyarrhythmia), QT prolongation, elevated blood pressure (including hypertension)

              Metabolic, nutritional: Hypokalemia, hyperglycemia

              Respiratory, thoracic, mediastinal: Asthma aggravation (potentially including cough, dyspnea, wheezing, bronchospasm)

              Vision blurred

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Primary treatment for acute bronchospasm, status asthmaticus, or exercise-induced bronchospasm

              Cautions

              Risk of LABAs used as monotherapy

              • Use of LABAs as monotherapy (without inhaled corticosteroids) for asthma is associated with an increased risk of asthma-related death
              • Data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patient
              • These findings are considered a class effect of LABA monotherapy
              • When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

              Fungal infections

              • Localized infections of the mouth and pharynx with Candida albicans reported; if oropharyngeal candidiasis develops, treat with appropriate local or systemic (i.e., oral) antifungal therapy while remaining on treatment; at times therapy may need to be interrupted
              • To reduce risk of oropharyngeal candidiasis, after dosing, advise patients to rinse their mouth with water and spit out the contents without swallowing

              Do not use to treat acutely deteriorating asthma or acute symptoms; additionally, increased inhaled short-acting beta agonist (SABA) use is marker of deteriorating asthma

              Do not use in combination with additional LABA, because of risk of overdose

              Localized Candida albicans infections develop in mouth and pharynx in some patients; to reduce risk, mouth must be rinsed after inhalation

              Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals; risk of more serious or fatal course of chickenpox or measles exists in susceptible patients (eg, unvaccinated or immunologically unexposed individuals); care must be taken to avoid exposure

              Because of possibility of systemic absorption of inhaled corticosteroids, patients should be observed carefully for any evidence of systemic corticosteroid effects; particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response

              Particular care is needed in switching patients from systemic to inhaled corticosteroids; potentially fatal adrenal insufficiency may occur before or afterward; taper withdrawal gradually

              During stress or severe asthma attack, patients who have been withdrawn from systemic corticosteroids should resume PO corticosteroids immediately

              Excessive use may suppress hypothalamic-pituitary-adrenal function; monitor closely, especially postoperatively or during periods of stress

              Risk of paradoxical bronchospasm, which may be life-threatening; discontinue, and treat immediately with inhaled SABA

              Cardiovascular and central nervous system (CNS) effects may occur as consequences of excess beta-adrenergic stimulation; may result in asthma-related death; caution must be exercised in patients with cardiovascular (eg, aneurysm, pheochromocytoma) or convulsive disorders or thyrotoxicosis

              Long-term administration of corticosteroids may decrease in bone mineral density; monitor patients at risk

              May decrease growth velocity in children

              Risk of cataracts, glaucoma, and increased intraocular pressure; consider referral to an ophthalmologist in patients who develop ocular symptoms or use therapy long term

              Risk of systemic eosinophilic conditions, some consistent with Churg-Strauss syndrome

              Risk of transient hypokalemia; supplementation may not be necessary

              Exercise caution when considering coadministration with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, telithromycin); consider benefit of coadministration versus potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects

              Prolonged treatment with corticosteroids associated with development of Kaposi sarcoma; consider discontinuing therapy if it occurs

              Psychiatric disturbances reported with corticoid use; therapy may exacerbate preexisting psychiatric conditions

              Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex infections may occur; more serious or even fatal course of chickenpox or measles can occur in susceptible patients; use with caution in patients with these infections because of potential for worsening of these infections

              Risk of impaired adrenal function when transferring from oral steroids; taper patients slowly from systemic corticosteroids if transferring to inhaler

              Hypercorticism and adrenal suppression; may occur with very high dosages or at regular dosage in susceptible individuals

              Decreases in bone mineral density; monitor patients with major risk factors for decreased bone mineral content

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy: There are no randomized clinical studies in pregnant women; there are clinical considerations with use in pregnant women In women with poorly or moderately controlled asthma, there is increased risk of several perinatal adverse outcomes such as preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate; pregnant women with asthma should be closely monitored and medication adjusted as necessary to maintain optimal asthma control

              Lactation: There are no available data on the presence of mometasone furoate, or formoterol fumarate in human milk; the effects on the breastfed child, or the effects on milk production; The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Mometasone: Glucocorticoid; elicits local anti-inflammatory effects on respiratory tract with minimal systemic absorption

              Formoterol: Long-acting selective beta2-adrenergic agonist with rapid onset of action; acts locally as bronchodilator; stimulates intracellular adenyl cyclase, which results in increased cyclic adenosine monophosphate levels, causing relaxation of bronchial smooth muscle and inhibition of release of mast cell mediators

              Absorption

              Peak plasma time: Mometasone, 1-2 hr; formoterol, 0.5-2 hr

              Peak plasma concentration: Mometasone, 20-60 pg/mL; formoterol, 22-125 pg/mL

              Distribution

              Protein bound: Mometasone, 98-99%; formoterol, 31-38%

              Vd: Mometasone, 152 L

              Metabolism

              Metabolized in liver by CYP3A4 (mometasone); glucuronidation and O-demethylation followed by conjugation (CYP2D6, CYP2C19, CYP2C9, and CYP2A6 involved in O-demethylation)

              Elimination

              Half-life: Mometasone, 25 hr; formoterol, 9-11 hr

              Total body clearance: Mometasone, 12.5 mL/min/kg; formoterol, 217 mL/min/kg

              Excretion (mometasone): Urine (8%), feces (74%)

              Excretion (formoterol): Urine (59-62%), feces (32-34%)

              Previous
              Next:

              Administration

              Oral Inhalation Preparation

              Priming

              • Prime inhaler before first use or when inhaler is unused for >5 days
              • Release 4 test puffs into air, away from face
              • Remove cap; shake well for 5 sec before each test puff

              Instructions

              • Check mouthpiece for objects before use
              • Make sure canister is fully inserted
              • Shake well before each use

              Oral Inhalation Administration

              For oral inhalation only

              Remove cap; place middle or index finger on canister top while placing thumb underneath mouthpiece

              Breathe out fully through your mouth, expelling as much air from lungs as possible; hold inhaler upright, placing the mouthpiece fully into the mouth, closing your lips around it

              While pushing firmly on canister top, continue breathing in slowly until lungs are full; avoid breathing out

              Hold breath as comfortably possible, up to 10 sec

              Remove inhaler from mouth; breathe through nose while keeping lips closed

              Repeating dose

              • Wait at least 30 seconds prior preceding second puff
              • Shake well prior to use; repeat steps (see under Oral Inhalation Administration)
              • Replace the cap after use
              • When finished administering 2 puffs, rinse mouth out with water (do not swallow water)

              Cleaning

              Wash and dry mouthpiece at least weekly

              When mouthpiece becomes blocked, wash mouthpiece thoroughly

              Storage

              Store at room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.